Regeneron Pharmaceuticals Inc (REGN) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Total Cash From Operating Activities Chart for Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc (REGN) operating cash flow for FY2025 was USD 5.0B, a 12.6% change from FY2024. Regeneron Pharmaceuticals Inc's operating cash flow moved from USD -6.8M in 1991 to USD 5.0B in 2025 over 34 years. Operating cash flow compound annual growth rate: 5-year CAGR of 13.7%, 10-year CAGR of 14.1%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$79.49B
Implied Share Price
$785.98
Enterprise Value
$73.03B
Revenue (TTM)
$15.53B
EBITDA
$4.70B
Profit Margin
27.87%
Trailing P/E
19.01
Forward P/E
16.61
Price/Book (MRQ)
2.47
Price/Sales (TTM)
5.12
EV/EBITDA
12.70
EV/Revenue
4.70
Dividend Yield
0.47%
Book Value
$316.11
Free Cash Flow (FY2025)
$4.08B
Free Cash Flow Yield
5.13%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.